MedTrace Logo

Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects

NCT03704675 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-04-14

No results posted yet for this study

Summary

Participants in this study will receive 200 milligram (mg) TEW-7197 taken at 7days apart. One dose will be given under fasting . The Other dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 2weeks not including screening.

Conditions

  • Healthy Volunteers

Interventions

DRUG

TEW-7197

Administered orally

Sponsors & Collaborators

  • MedPacto, Inc.

    lead INDUSTRY

Principal Investigators

  • Sunjin Hwang, MD · MedPacto, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-08
Primary Completion
2018-09-09
Completion
2018-10-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03704675 on ClinicalTrials.gov